DNAlysis, established in 2008, remains at the forefront of delivering personalised medicine services in South Africa and globally. Widely acknowledged as an industry leader, the DNAlysis team is relied upon by numerous doctors and healthcare practitioners worldwide for support and training. The tests have earned a reputation for its clinical relevance and scientific robustness. Operating ISO-accredited laboratories in Johannesburg and Helsinki, they process over 2000 DNA samples monthly, focusing on Nutrigenomics, Pharmacogenomics, Ancestry, and Risk Screening.
In the realm of Pharmacogenomics, where over 4 billion drugs are prescribed annually, a substantial portion (between 38-75 percent) proves ineffective. Doctors, burdened and fatigued, and patients, with limited time spent with healthcare providers, frequently encounter unpleasant side effects or struggle with the safe usage of prescribed medications.
Adopting a more personalised approach to medicine can not only save lives but also mitigate medication-related side effects.
Pharmacogenomics (PGx) is a rapidly expanding field exploring how an individual’s genome influences their response to medication. It provides a cost-effective alternative to the trial-and-error method in prescribing medication. Laboratories and healthcare providers embracing PGx testing can deliver improved outcomes, reduced costs, and a more personalised healthcare experience. The U.S. Food and Drug Administration has incorporated pharmacogenomic information into over 200 medications. By appropriately integrating PGx into clinical practice, well-supported and readily available data can become a standard part of healthcare.